It will be meaningful to explore CDK4 level in cases with either CDK6 high level or low level and evaluate the influence of CDK4 expression on the sensitivity to CDK4/6 inhibitors in BLCA in the next step. This evidence concerns the gene CDK6 and bladder transitional cell carcinoma.